From WikiProjectMed
Jump to navigation Jump to search
Doravirine structure.svg
Trade namesPifeltro
Other namesMK-1439
  • 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile
Clinical data
Drug classNon-nucleoside reverse transcriptase inhibitor (NNRTI)[1]
Main usesHIV/AIDS[1]
Side effectsNausea, dizziness, headache, tiredness, diarrhea, abnormal dreams[1]
Routes of
By mouth[1]
Typical dose100 mg OD[2]
External links
License data
Legal status
Chemical and physical data
Molar mass425.75 g·mol−1
3D model (JSmol)
  • Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F
  • InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)

Doravirine, sold under the brand name Pifeltro, is a medication used to treat HIV/AIDS.[1] It is taken together with other HIV medicines.[1] It is taken by mouth, generally once per day.[1]

Common side effects include nausea, dizziness, headache, tiredness, diarrhea, and abnormal dreams.[1] Other side effects may include immune reconstitution syndrome.[1] Safety in pregnancy is unclear.[4] It is a non-nucleoside reverse transcriptase inhibitor (NNRTI).[1]

Doravirine was approved for medical use in the United States and Europe in 2018.[2] In the United Kingdom a month of medication costs the NHS about £470 as of 2021.[5] This amount in the United States is about 1,500 USD.[6] It is also available as the combination doravirine/lamivudine/tenofovir.[5]

Medical uses


It is generally taken at a dose of 100 mg per day.[2]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Archived from the original on 28 October 2020. Retrieved 22 September 2020.
  2. 2.0 2.1 2.2 2.3 "Pifeltro EPAR". European Medicines Agency (EMA). Archived from the original on 28 October 2020. Retrieved 1 October 2020.
  3. "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 26 September 2020. Retrieved 1 October 2020.
  4. "Doravirine (Pifeltro) Use During Pregnancy". Archived from the original on 3 December 2020. Retrieved 27 December 2021.
  5. 5.0 5.1 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 683. ISBN 978-0857114105.
  6. "Pifeltro Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 27 December 2021.

External links

External sites: